Last reviewed · How we verify
Short Course Adjuvent Chemotherapy
Short Course Adjuvent Chemotherapy involves administering a limited course of chemotherapy to enhance the effectiveness of radiation therapy.
Short Course Adjuvent Chemotherapy involves administering a limited course of chemotherapy to enhance the effectiveness of radiation therapy. Used for Locally advanced or metastatic cancer.
At a glance
| Generic name | Short Course Adjuvent Chemotherapy |
|---|---|
| Sponsor | Trans Tasman Radiation Oncology Group |
| Drug class | Chemotherapeutic agent |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
This approach aims to increase the sensitivity of cancer cells to radiation, thereby improving treatment outcomes. The chemotherapy agents used in this regimen are typically cytotoxic and work by interfering with DNA replication and cell division.
Approved indications
- Locally advanced or metastatic cancer
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Nausea and vomiting
- Diarrhea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: